中文
About Us
Corporate Overview
Management Team
Board of Directors
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipline
Overview
HCV
HBV
ASC09
ASC06
Partnership
Investors
Financials & Filing
Presentation Materials
News
2020
2019
2018
2017
2016
2015
2014
Careers
Investors
Financials & Filing
Presentation Materials
Grant of Share Options
2020-03-31
2019 Annual Results
2020-03-24
Notice of Board Meeting
2020-03-11
Announcement - Inside Information - Progress of the Small Sample Clinical Trial of Ganovo (Danoprevir) and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-03-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020
2020-03-03
Announcement - Inside Information - Clinical Trial of Ganovo and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-02-27
Voluntary Announcement - Application for Category I Drug ASC41 for Clinical Trials of Nonalcoholic Steatohepatitis (NASH) Indication Accepted
2020-02-18
Announcement - Inside Information - Ritonavir Obtained Approval from Relevant Regulatory Authorities of Zhejiang Province to Conduct Study on the Treatment of Novel Coronavirus Pneumonia
2020-02-17
Announcement - Inside Information - ASC09/Ritonavir Combined with Interferon Alpha Atomization Obtained Approval from the Second Affiliated Hospital Ethics Committee of Chongqing Medical University to Conduct Clinical Trial on the Treatment of Novel Coron
2020-02-13
Announcement - Inside Information - ASC09/Ritonavir Clinical Trial for New Coronavirus Infection Initiated across Zhejiang Province after Wuhan
2020-02-07
«
2
3
4
5
»
